Iris Pharma, the ophthalmology-focused contract research organisation based in Nice, France, has announced a strategic alliance with US-headquartered preclinical specialist RxGen offering integrated ‘bench-to-bedside’ ophthalmology research services to the pharmaceutical and biotechnology industries.

Under the alliance, Iris Pharma’s clients will get immediate access to RxGen’s non-human primate ophthalmic research models and related preclinical in vivo services, via a “flexible engagement” model that “allows customers to benefit from the combined preclinical and clinical insight, capabilities, and expertise” of the new partners.   

Based in Hamden, Connecticut, RxGen provides a range of services from proof-of-concept through to regulatory studies, applying in vivo disease models and pharmacokinetic, pharmacodynamic and safety assessments. Its therapeutic focus spans central nervous system, metabolic and cardiac diseases and disorders as well as ophthalmology.  

Iris Pharma’s offering includes proof-of-concept and Good Laboratory Practice-compliant preclinical studies (safety, tolerance, pharmacokinetics, efficacy), bioanalysis, preclinical formulation, clinical trials and consulting services.